Suppr超能文献

大剂量化疗后仅通过外周血干细胞输注实现快速且持续的造血重建。

Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy.

作者信息

Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, West W

机构信息

Clinical Trials Division, Response Technologies Inc., Memphis, TN.

出版信息

Bone Marrow Transplant. 1993 May;11(5):369-74.

PMID:8099300
Abstract

We utilized mobilized peripheral blood stem cells (PBSC) as sole support for hematologic reconstitution following high-dose chemotherapy in 52 patients with advanced solid tumors and lymphoma. PBSC were collected by large scale leukapheresis after mobilization with chemotherapy. Each apheresis product was analysed for total nucleated cells, CFU-GM and CD34+ content. Disease-specific high-dose chemotherapy regimens were administered followed by thawed PBSC. Colony-stimulating factors were not administered. The median time to an absolute neutrophil count > 0.5 x 10(9)/l was 13 days (range 9-26 days) and median time to a sustained platelet count > 20 x 10(9)/l without transfusion support was 10 days (range 5-43 + days). There was no difference in time to recovery by dose-intensive regimen or underlying disease. The times to recover ANC and platelets both correlated significantly with increasing doses of PBSC as assayed by CD34+ cells and CFU-GM. All four patients with prolonged platelet recovery times received < 20 x 10(4) CFU-GM/kg, establishing this as a threshold value for PBSC infusion. There were no late transient or sustained graft failures. For 26 patients alive 1 year after infusion, the mean total leukocyte count is 6.3 x 10(9)/l, mean hematocrit 35.5% and mean platelet count 182 x 10(9)/l. Thirteen patients followed at least 24 months after PBSC infusion have essentially normal blood counts. Mobilized peripheral blood progenitors are an effective source of stem cells which afford rapid and complete hematopoietic engraftment after myelo-suppressive chemotherapy regimens. Engraftment appears sustained with no late failures.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们采用动员的外周血干细胞(PBSC)作为52例晚期实体瘤和淋巴瘤患者大剂量化疗后血液重建的唯一支持。PBSC在化疗动员后通过大规模白细胞单采术采集。对每份单采产品进行有核细胞总数、粒-巨噬细胞集落形成单位(CFU-GM)和CD34+含量分析。给予疾病特异性大剂量化疗方案,随后输注解冻的PBSC。未给予集落刺激因子。绝对中性粒细胞计数>0.5×10⁹/L的中位时间为13天(范围9 - 26天),在无输血支持情况下血小板持续计数>20×10⁹/L的中位时间为10天(范围5 - 43 +天)。剂量密集方案或基础疾病对恢复时间无差异。中性粒细胞计数和血小板恢复时间均与通过CD34+细胞和CFU-GM测定的PBSC剂量增加显著相关。所有4例血小板恢复时间延长的患者接受的CFU-GM/kg<20×10⁴,将此确定为PBSC输注的阈值。无晚期短暂或持续性移植物失败。对于输注后1年存活的26例患者,平均白细胞总数为6.3×10⁹/L,平均血细胞比容为35.5%,平均血小板计数为182×10⁹/L。13例在PBSC输注后至少随访24个月的患者血细胞计数基本正常。动员的外周血祖细胞是一种有效的干细胞来源,在骨髓抑制化疗方案后能实现快速且完全的造血植入。植入似乎持续存在,无晚期失败情况。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验